These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 32466800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
    Zhang WL, Lou D, Zhang DT, Zhang Y, Huang HJ.
    J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.
    Li Z, Yang S, Hua Z, Lu Y, Li X.
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3351-3362. PubMed ID: 37950768
    [Abstract] [Full Text] [Related]

  • 6. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD, Alberio L, Angelillo-Scherrer A, Asmis LM, Fontana P, Korte W, Mendez A, Schmid P, Stricker H, Tsakiris DA, Wuillemin WA, Nagler M.
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
    Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, Knabbe C, Birschmann I.
    PLoS One; 2015 Aug; 10(12):e0145478. PubMed ID: 26699714
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-Xa Activity Monitoring for Optimizing Rivaroxaban Dosage in Chinese Patients with Cerebral Venous Thrombosis.
    Zhang X, Gao M, Lan D, Wang Z, Fang K, Ren X, Liu N, Zhou D, Ji X, Meng R.
    Clin Appl Thromb Hemost; 2024 Aug; 30():10760296241286507. PubMed ID: 39314176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS.
    Liu H, Zhao Z, Wang Y, Liu L, Yang Y, An Z.
    Curr Drug Metab; 2021 Aug; 22(14):1132-1138. PubMed ID: 34825867
    [Abstract] [Full Text] [Related]

  • 16. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H, Rasmusson A, Söderblom L, Malmström RE, Antovic J.
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A validated UPLC-MS/MS method for the determination of CX3002 in human plasma and its application to a pharmacokinetic study.
    Hu X, Xu Y, Chen J, Shen Y, Yang D, Hu Y, Jiang B, Lou H, Ruan Z.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct 15; 1183():122954. PubMed ID: 34628186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.